Testing of integrated human papillomavirus mrna decreases colposcopy referrals: Could a change in human papillomavirus detection methodology lead to more cost-effective patient care?

Acta Cytologica

Volumn 58, Issue 2, 2014, Pages 162-166

  Sauter, Jennifer L ^a   Mount, Sharon L ^a   St John, Timothy L ^b   Wojewoda, Christina M ^a   Bryant, Ronald J ^a   Leiman, Gladwyn ^a  

^a FLETCHER ALLEN HEALTH CARE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

APTIMA; ASCUS triage; Cervical cancer screening; Cervix; Human papillomavirus; Hybrid capture; Integrated mRNA; Molecular and diagnostic gynecologic cytopathology; Squamous neoplasia; Virology

Indexed keywords

MESSENGER RNA; VIRUS MESSENGER RNA;

ADULT; AGED; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; FEMALE; HIV RAPID TEST; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIDDLE AGED; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; SQUAMOUS CELL; STATISTICAL ANALYSIS; YOUNG ADULT; APTIMA; CLINICAL LABORATORY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CYTOPATHOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; HIGH RISK PATIENT; HUMAN TISSUE; LABORATORY DIAGNOSIS; MEDICAL SOCIETY; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; RAPID TEST; VIRAL LOAD TESTING; VIRUS DETECTION;

HUMAN PAPILLOMAVIRUS;

CERVIX UTERI; COLPOSCOPY; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT CARE; RNA, MESSENGER; VAGINAL SMEARS;

EID: 84897465716     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000358246     Document Type: Article

References (11)

1. ® HPV Assay-P100042. 2008. http://www.fda.gov/ MedicalDevices/ProductsandMedicalProce-dures/DeviceApprovalsandClearances/ Re-cently-ApprovedDevices/ucm278520.htm (accessed September 8, 2013).
2. GEN-PROBE APTIMA HPV Assay Package Insert. 2011. http://www.gen-probe. com/pdfs/pi/5021-70-EN-RevA.pdf (accessed September 8, 2013).
3. Hopman AN, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, Vooijs GP, Speel EM, Ramaekers FS: Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004; 202:23-33.
4. Kjaer SK, van den Brule AC, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CM: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.
5. Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32:S16-S24.
6. Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, Sankaranarayanan R, Schiller J, Singer A, Wright TC Jr, Kinney W, Meijer CM, Linder J, McGoogan E, Meijer C, Wright T: Cervical cancer control, priorities and new directions. Int J Cancer 2004; 108: 329-333.
7. Doorbar J: Molecular biology of human papil-lomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110:525-541.
8. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, Smith JS: Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE Study. Int J Cancer 2011; 129: 691-701.
9. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C: Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009; 45:S55-S61.
10. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL, Monsonego J: The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 2013; 132: 101-108.
11. Dixon WJ, Massey FJ: Introduction to Statistical Analysis. New York, McGraw-Hill, 1969.